Author： Raghav Kanwal Pratap Singh Blumenschein George R
Publisher： Informa Healthcare
ISSN： 1354-3784
Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.6, 2011-06, pp. : 859-869
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Docetaxel + cisplatin active in advanced NSCLC
Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. :
Access to resources
Recommend
Oxaliplatin plus paclitaxel in advanced NSCLC
Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. :
In erlotinib we TRUST to treat advanced NSCLC
Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. :
S-1 + cisplatin promising for advanced NSCLC
Inpharma, Vol. 1, Iss. 1475, 2005-01 ,pp. :
Bevacizumab combination improves survival in advanced NSCLC
Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. :